17909名婚检青年HBsAg阳性率分析

为了解婚检青年乙肝感染状况 ,我们对 1995～ 2 0 0 0年婚检青年携带ＨＢｓＡｇ状况进行了调查 ,现将结果报告如下。对象与方法1　对象　 1995～ 2 0 0 0年来自越城区 5乡 1镇的 1795 0名参加婚检青年 ,其中资料完整 1790 9名。年龄 2 0～ 36周岁 ,平均 2 4 3周岁 ;其中男性 8947名 ,女性 896 2名。2　方法　婚检青年除物理体检外 ,辅助项目肝功能(ＳＧＰＴ、ＴｉＢ)及乙肝表面抗原检测为常规 ,如发现乙肝表面抗原阳性 ,在征得体检对象同意的情况下 ,作乙肝三系检查。ＨＢｓＡｇ检测用ＥＬＩＳＡ法 ,乙肝三系试剂由厦门新创科技有限公司提供…     

68Ga-DOTA-NOC胰腺癌生长抑素受体靶向显像的实验研究

目的 研究68 Ga-1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸-1-萘丙氨酸-奥曲肽(DOTA-NOC)在小鼠体内的生物分布,并进行荷胰腺癌小鼠的68Ga-DOTA-NOC SSTR靶向显像.方法 37 MBq 68GaCl2加入20μl羟乙基哌嗪乙硫磺酸(HEPES,0.1 mmol/L)溶液和10～50 μg DOTA-NOC,于95℃水浴加热15 min制备68Ga-DOTA-NOC.采用HPLC法分析68 Ga-DOTA-NOC的标记率及体外稳定性.予正常BALB/c小鼠尾静脉注射68Ga-DOTA-NOC 3.7 MBq,分别在5、15、30、60和120 min后解剖分离小鼠脏器,测放射性生物分布(％ID/g)情况.将人CFPAC-1胰腺癌细胞与68Ga-DOTANOC共同孵育后,测定放射性计数并计算摄取率.建立CFPAC-1荷瘤裸鼠模型,行microPET显像,勾画ROI,获得肿瘤及主要脏器TAC,计算T/NT(NT为对侧肌肉).用流式细胞术检测CFPAC-1细胞及瘤体SSTR表达水平,采用直线相关分析对SSTR表达率与T/NT行相关性研究.结果 68 Ga-DOTA-NOC标记率为(98.8±1.0)％,无需纯化.正常小鼠体内68Ga-DOTA-NOC肾摄取最多,5 min为(11.20±0.32) ％ID/g,随时间延长减少,60 min为(4.11±0.21)％ID/g,胰腺、肺、胃相对摄取较高,脑几乎无摄取.人CFPAC-1细胞可特异性摄取68Ga-DOTA-NOC.荷瘤鼠microPET显像示CFPAC-1肿瘤部位呈异常放射性摄取,T/NT在120 min达3.2±0.2.CFPAC-1细胞和肿瘤组织SSTR1、2、4、5表达量分别为(96.83±1.23)％、(99.73±0.98)％、(90.42±0.63)％和(92.96±0.71)％,SSTR2、5的表达水平与T/NT均呈正相关(r=0.71、0.80,均P＜0.05).结论 68 Ga-DOTA-NOC易标记,生物分布理想,可靶向结合SSTR阳性的CFPAC-1肿瘤组织.68Ga-DOTA-NOC是新型SSTR靶向显像剂,有利于胰腺肿瘤的早期诊断并为生长抑素介导靶向治疗提供依据.     

运脾活血法对2型糖尿病血脂异常的临床研究

目的:探讨运脾活血法对2型糖尿病血脂异常患者在调脂方面的作用。方法:56例中医证属脾气亏虚、瘀血阻滞的2型糖尿病血脂异常患者随机分为治疗组(运脾活血法组)30例和对照组(二甲双胍片组)26例,疗程3个月。结果:两组治疗前后FPG、HbA1C、BMI、TC、TG、HDL-C均有显著差异(P<0.05),治疗组经治疗后的TG、HDL-C与对照组比较,差异有统计学意义(P<0.05)。     

海洛因戒断后病毒性心肌炎45例临床分析

目的:通过对强制隔离戒毒所内海洛因依赖戒毒后病毒性心肌炎的症状,辅助检查,诊治及相关因素给予分析,便于一线临床工作者经验的交流。方法:2010年5月~2010年11月期间在东莞市强制戒毒所内共45例病毒性心肌炎患者的统计分析。结果:病毒性心肌炎在海洛因依赖戒毒后的发病及死亡率较高,通过临床表现及辅助检查,及早的综合治疗,效果明显。结论:强制隔离戒毒所内病毒性心肌炎的治疗及相关因素给予改善,对预防疾病的发生和治疗有较大帮助。     

肺栓塞诊断中SPECT/CT融合显像技术与肺通气/灌注平面显像方法的比较

目的:探讨SPECT/CT融合显像技术在诊断肺动脉栓塞(pulmonary embolism,PE)中的价值?方法:45例PE疑似患者分别行常规肺通气/灌注(V/P)平面显像及SPECT/CT断层融合显像,比较两种检测方法诊断PE的敏感性?特异性?准确性的差异?结果:常规肺V/P显像的敏感性?特异性?准确性分别为78.6%?58.8%和71.1%,SPECT/CT断层融合显像的敏感性?特异性?准确性分别为92.9%?88.2%和91.1%,两种影像学检查在定性诊断PE方面有统计学差异(χ2=14.63,P < 0.05)?结论:SPECT/CT肺断层融合显像法优于常规肺V/P显像,可作为诊断PE的一种新的常规检测方法?     

32P-磷酸铬-聚-L-乳酸粒子植入治疗裸鼠荷人胰腺癌移植瘤的研究

目的 探讨32p-磷酸铬-聚-L-乳酸(32P-CP-PLLA)粒子瘤体间质给药治疗BALB/c裸鼠荷人胰腺癌( BxPc-3)移植瘤的药效学及全身不良反应.方法 24只荷瘤裸鼠,随机分为4组:空白对照组、37.0、18.5、9.3 MBq组.经瘤体分别给予剂量为0、9.3、18.5和37.0 MBq 32p-CP-P...     

32P-磷酸铬-聚 L-乳酸缓释粒子的制备及其放射性释出和生物分布

Objective The aim of this study was to prepare the 32P-chromic phosphate-poly(L-lac-tide) (32P-CP-PLLA) particles with different ratio of the materials and further examine their performance in-dex in vivo and in vitro and their intracorporeal distribution. Methods The erosion, degrading rates, de-layed release velocity and radioactivity self-absorption coefficient (RSAC) of 32P-CP-PLLA particles made from different materials were investigated and compared. After the implantation of 32P-CP-PLLA particles and the injection of 32P-CP colloids in the muscular tissues, the weight loss rate and the radioactivity release rate (RRR) of the particles were calculated. The intracorporeal distribution, radioactive half-life and bio-logical effect of 32P in the targeting sites were further studied. Statistical analysis was performed with SPSS 12.0, and one-way analysis of variance and t-test were used. Results 32P-CP-PLLA particles were of green cylinder, with regular shape and radionuclide distribution. The RSAC of the particles was of little re-lation with molecular weight of PLLA and proportional to the ratio of PLLA to CP. The extracorporeal release rate increased with the reduction of molecular weight of PLLA and with the increase of the ratio of PLLA to CP. The RRR reached peak when PLLA was 3 times of CP. The 32P-CP, released with the degradation and corrosion of the particle distributed mainly in the surrounding muscles of the particle. And the peak of per-centage activity of injection dose per gram of tissue (% ID/g) in liver, spleen and bone were 1. 7887, 1. 6401 and 1. 9470 respectively, much lower than that in the 32P-CP group (4.7523, 3.9712 and 4.3174 ; all t > 2.7, all P < 0.05). The % ID/g in other organs was much less. The radioactivity effective half-life in the targeting sites increased to about 13 d. There was widespread necrosis around the particles with no ex-istence of normal tissues among them. And no abnormality in spleen and liver was found. Conclusion As a better dosage form of pure β-particle emitter, 32P-CP-PLLA, which can increase the targeting radioactive dosage and effective half-life in the implanting sites, can be served as an potential implanting agent for onco-therapy with a better perspective.     

131I和抗甲状腺药物治疗糖尿病合并甲状腺机能亢进症临床观察

目的:评价131I治疗糖尿病合并甲状腺机能亢进症的临床疗效.方法:57例糖尿病合并甲状腺机能亢进症患者分为131I治疗组(27例)和抗甲状腺药物对照组(30例),于治疗后观察1～3年,比较2组的疗效、胰岛素的使用、甲状腺机能亢进症复发率、甲状腺功能减退症发生率及治疗的不良反应.结果:治疗组治疗后的总有效率81.5%,明显高于对照组(53.3%).差异有统计学意义(χ2=7.1,P<0.01);2例患者原使用胰岛素后改为口服降糖药(2/8,25%).对照组甲状腺机能亢进症复发率(56.7%)和不良反应发生率(26.7%)明显高于治疗组(7.1%,0%),2组差异有统计学意义(χ2=9.04,P<0.01,χ2=10.37,P<0.01).结论:131I治疗糖尿病合并甲状腺机能亢进症优于抗甲状腺药物,疗效好、不良反应少.     

32P-磷酸铬-聚 L-乳酸缓释粒子的制备及其放射性释出和生物分布

Objective The aim of this study was to prepare the 32P-chromic phosphate-poly(L-lac-tide) (32P-CP-PLLA) particles with different ratio of the materials and further examine their performance in-dex in vivo and in vitro and their intracorporeal distribution. Methods The erosion, degrading rates, de-layed release velocity and radioactivity self-absorption coefficient (RSAC) of 32P-CP-PLLA particles made from different materials were investigated and compared. After the implantation of 32P-CP-PLLA particles and the injection of 32P-CP colloids in the muscular tissues, the weight loss rate and the radioactivity release rate (RRR) of the particles were calculated. The intracorporeal distribution, radioactive half-life and bio-logical effect of 32P in the targeting sites were further studied. Statistical analysis was performed with SPSS 12.0, and one-way analysis of variance and t-test were used. Results 32P-CP-PLLA particles were of green cylinder, with regular shape and radionuclide distribution. The RSAC of the particles was of little re-lation with molecular weight of PLLA and proportional to the ratio of PLLA to CP. The extracorporeal release rate increased with the reduction of molecular weight of PLLA and with the increase of the ratio of PLLA to CP. The RRR reached peak when PLLA was 3 times of CP. The 32P-CP, released with the degradation and corrosion of the particle distributed mainly in the surrounding muscles of the particle. And the peak of per-centage activity of injection dose per gram of tissue (% ID/g) in liver, spleen and bone were 1. 7887, 1. 6401 and 1. 9470 respectively, much lower than that in the 32P-CP group (4.7523, 3.9712 and 4.3174 ; all t > 2.7, all P < 0.05). The % ID/g in other organs was much less. The radioactivity effective half-life in the targeting sites increased to about 13 d. There was widespread necrosis around the particles with no ex-istence of normal tissues among them. And no abnormality in spleen and liver was found. Conclusion As a better dosage form of pure β-particle emitter, 32P-CP-PLLA, which can increase the targeting radioactive dosage and effective half-life in the implanting sites, can be served as an potential implanting agent for onco-therapy with a better perspective.